临床药师参与化疗所致恶心、呕吐管理的效果评价-东南大学学报医学版

临床药师参与化疗所致恶心、呕吐管理的效果评价

单位：1. 盱眙县人民医院药剂科, 江苏淮安 211700;
2. 盱眙县人民医院麻醉科, 江苏淮安 211700

分类号：R979.1

出版年·卷·期（页码）：2026·45·第一期（85-90）

摘要：

目的:探讨临床药师在非小细胞肺癌(NSCLC)患者化疗导致的恶心、呕吐(CINV)管理中的作用和效果。方法:以本院2024年收治的NSCLC患者为研究对象,随机分为对照组和干预组。干预组患者入院后由临床药师进行入院风险评估、止吐方案制定和调整、药学监护、用药指导、健康宣教等一系列药学干预。对照组医生根据经验性诊疗方案进行恶心、呕吐管理。比较两组患者CINV发生率及严重程度、住院时长及费用等方面的差异。结果:干预组急性及延迟性恶心、呕吐发生率及严重程度均低于对照组,差异具有统计学意义(P<0.05),尤其临床药师在接受高致吐风险化疗的患者中的干预效果更好。虽然干预组患者中位住院时长和中位药品费用均较对照组降低,但两组患者在药品费用、住院费用、住院时长上差异均无统计学意义(P>0.05)。干预组患者满意度得分高于对照组(P<0.01)。结论:临床药师参与CINV管理可显著降低CINV发生率和严重程度,提高NSCLC患者生活质量和满意度,并在一定程度上降低住院时长和治疗成本。

Objective: To explore the role and effectiveness of clinical pharmacists in the management of chemotherapy-induced nausea and vomiting(CINV) in patients with non-small cell lung cancer(NSCLC). Methods: Patients with NSCLC admitted to our hospital in 2024 were selected as the research subjects and randomly divided into a control group and an intervention group. Patients in the intervention group received a series of pharmaceutical interventions from clinical pharmacists upon admission, including risk assessment, formulation and adjustment of antiemetic regimens, pharmaceutical care, medication guidance, and health education. Nausea and vomiting in the control group were managed with empirical treatment regimens by attending physicians. The differences in the incidence and severity of CINV, length of hospital stay, costs and patient satisfaction were analyzed between the two groups. Results: Compared with the control group, the incidence and severity of acute and delayed nausea and vomiting in the intervention group were lower(P<0.05), especially in patients receiving highly emetogenic chemotherapy. The satisfaction score of patients in the intervention group was higher than that of the control group(P<0.01). The median length of hospital stay and medication costs in the intervention group were both lower than those in the control group. However, there were no statistically significant differences of drug costs, hospitalization costs, and length of hospital stay between the two groups(all P>0.05). Conclusion: The participation of clinical pharmacists in CINV management significantly reduced the incidence and severity of CINV, improved the quality of life and satisfaction of patients with NSCLC, and reduced hospital stay and treatment costs to a certain extent.

参考文献：

[1] 陆文清,孟周文理,虞永峰,等.非小细胞肺癌第三代表皮生长因子受体-酪氨酸激酶抑制剂的耐药机制及治疗策略[J].上海交通大学学报(医学版),2022,42(4):535-544.
[2] 付文慧,刘雯,黄毅力,等.中晚期非小细胞肺癌调强放疗联合化疗前后血清VEGF、CEA、NSE和CYFRA21-1的表达及其临床意义[J].现代医学,2023,51(4):501-505.
[3] PIECHOTTA V,ADAMS A,HAQUE M,et al.Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy:a network meta-analysis[J].Cochrane Database Syst Rev,2021,11(11):CD012775.
[4] WOOPEN H,RICHTER R,CHEKEROV R,et al.Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients:results of an individual participant data meta-analysis in 1213[J].Support Care Cancer,2020,28(1):73-78.
[5] AAPRO M.CINV:still troubling patients after all these years[J].Support Care Cancer,2018,26(Suppl 1):5-9.
[6] 李香风,刘薇,秦瑛,等.中文版 MASCC止吐评价的信效度评价[J].中华现代护理杂志,2016,22(19):2669-2673.
[7] TAN J Y,SUEN L K P,MOLASSIOTIS A.Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool(MAT) for measuring chemotherapy-induced nausea and vomiting[J].Support Care Cancer,2016,24(9):3729-3737.
[8] 张玉.化疗所致恶心呕吐的药物防治指南[J].中国医院药学杂志,2022,42(5):457-473.
[9] National Cancer Institute.Common terminology criteria for adverse events(CTCAE)[EB/OL].[2024-03-27].https://evs.nci.nih.gov/ftp1/CTCAE/About.html.
[10] 中国抗癌协会癌症康复与姑息治疗专业委员会,中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会,等.中国抗肿瘤治疗相关恶心呕吐预防和治疗指南(2023版)[J].中华肿瘤杂志,2024,46(6):481-501.
[11] National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:antiemesis 2024,Version 2.[EB/OL].[2025-03-08].https://wiki.shawnyu.org/lib/exe/fetch.php?media=public:nccn:antiemesis.pdf.
[12] 任丹君,张娟利,刘美佑,等.我院肿瘤化疗患者止吐药物使用的合理性分析[J].中国药房,2024,35(12):1495-1499.
[13] HESKETH P J,KRIS M G,BASCH E,et al.Antiemetics:American Society of Clinical Oncology clinical practice guideline update[J].J Clin Oncol,2017,35(28):3240-3261.
[14] 张翔,姜莹莹,施玥,等.福沙匹坦预防中重度致吐性方案所致化疗相关性呕吐的临床研究[J].现代医学,2022,50(10):1269-1274.
[15] KRIS M G,TONATO M,BRIA E,et al.Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy[J].Support Care Cancer,2011,19(Suppl 1):S25-S32.
[16] OLVER I,CLARK-SNOW R,RUHLMANN C H,et al.2023 updated MASCC/ESMO consensus recommendations:controlling nausea and vomiting with chemotherapy of low or minimal emetic potential[J].Support Care Cancer,2023,32(1):37.
[17] 谭晓杰.药品集采制度下药品费用智能管控的探讨[J].商业会计,2025(4):118-121.
[18] KRISHNARAJAN D,SIVASAKTHI K,ARIYAMOL R,et al.A prospective observational study of chemotherapy-induced adverse drug reaction and the quality of life in cancer patients in a tertiary care hospital[J].J Cancer Res Ther,2021,17(2):530-536.
[19] 赵洋,马泉吉,吴建章,等.临床药师干预对脑卒中患者合理使用依达拉奉右莰醇注射用浓溶液的效果分析[J].中国医院用药评价与分析,2024,24(8):1007-1009,1015.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录